NYSE American - Delayed Quote USD

VolitionRx Limited (VNRX)

Compare
0.6499
-0.0021
(-0.32%)
As of 2:37:20 PM EST. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,285.8270
775.3020
306.3920
90.0350
13.4330
Operating Expense
31,184.6530
36,548.5460
30,857.0390
26,900.5810
20,625.7350
Operating Income
-29,898.8260
-35,773.2440
-30,550.6470
-26,810.5460
-20,612.3020
Net Non Operating Interest Income Expense
-287.8990
-128.2980
-47.8220
-153.0690
-80.3040
Other Income Expense
-13.7330
224.4680
--
-26.1660
293.3120
Pretax Income
-30,200.4580
-35,677.0740
-30,598.4690
-26,989.7810
-20,399.2940
Net Income Common Stockholders
-29,872.7130
-35,319.0780
-30,268.7930
-26,814.6650
-20,352.1150
Diluted NI Available to Com Stockholders
-29,872.7130
-35,319.0780
-30,268.7930
-26,814.6650
-20,352.1150
Basic EPS
-0.36
-0.50
-0.55
-0.51
-0.45
Diluted EPS
-0.36
-0.50
-0.55
-0.51
-0.45
Basic Average Shares
82,987.6750
71,234.5650
55,350.4010
52,655.8850
45,278.8470
Diluted Average Shares
82,987.6750
71,234.5650
55,350.4010
52,655.8850
45,278.8470
Total Operating Income as Reported
-29,984.2040
-35,987.6950
-31,780.0720
-28,333.0790
-21,247.8150
Total Expenses
31,184.6530
36,548.5460
30,857.0390
26,900.5810
20,625.7350
Interest Income
17.9710
93.3240
125.2650
2.7340
49.4950
Interest Expense
305.8700
221.6220
173.0870
155.8030
129.7990
Net Interest Income
-287.8990
-128.2980
-47.8220
-153.0690
-80.3040
Net Income from Continuing & Discontinued Operation
-29,872.7130
-35,319.0780
-30,268.7930
-26,814.6650
-20,352.1150
Normalized Income
-29,858.9800
-35,543.5460
-30,268.7930
-26,788.4990
-20,645.4270
EBIT
-29,894.5880
-35,455.4520
-30,425.3820
-26,833.9780
-20,269.4950
EBITDA
-28,544.4790
-34,042.1750
-29,235.4340
-25,688.8180
-19,228.1220
Reconciled Depreciation
1,350.1090
1,413.2770
1,189.9480
1,145.1600
1,041.3730
Net Income from Continuing Operation Net Minority Interest
-29,872.7130
-35,319.0780
-30,268.7930
-26,814.6650
-20,352.1150
Total Unusual Items Excluding Goodwill
-13.7330
224.4680
--
-26.1660
293.3120
Total Unusual Items
-13.7330
224.4680
--
-26.1660
293.3120
Normalized EBITDA
-28,530.7460
-34,266.6430
-29,235.4340
-25,662.6520
-19,521.4340
12/31/2020 - 3/2/2012

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

OCX OncoCyte Corporation
2.0811
-5.83%
 
BIAF bioAffinity Technologies, Inc.
0.7400
-8.55%
 
ATLN Atlantic International Corp.
5.10
-0.58%
 
PRPH ProPhase Labs, Inc.
0.6490
0.00%
 
SZLS.TO StageZero Life Sciences Ltd.
0.0400
0.00%
 
ICBU iMD Companies, Inc.
0.0024
0.00%
 
ACRS Aclaris Therapeutics, Inc.
2.4600
-0.40%
 
GENE Genetic Technologies Limited
0.7650
0.00%
 
IDXG Interpace Biosciences, Inc.
0.6200
-27.06%
 
XWEL XWELL, Inc.
1.3999
+0.71%